CoChat

The DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.

Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems

Open access
Poudel, Prashant, Park, Soyeun · 2022 · Pharmaceutics

Abstract

Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disorder. Most existing treatments only provide symptomatic solutions. Here, we introduce currently available commercial drugs and new therapeutics, including repositioned drugs, to treat AD. Despite tremendous efforts, treatments targeting the hallmarks of AD show limited efficacy. Challenges in treating AD are partly caused by difficulties in penetrating the blood–brain barrier (BBB). Recently, nanoparticle (NP)-based systems have shown promising potential as precision medicines that can effectively penetrate the BBB and enhance the targeting ability of numerous drugs. Here, we describe how NPs enter the brain by crossing, avoiding, or disrupting the BBB. In addition, we provide an overview of the action of NPs in the microenvironment of the brain for the treatment of AD. Diverse systems, including liposomes, micelles, polymeric NPs, solid-lipid NPs, and inorganic NPs, have been investigated for NP drug loading to relieve AD symptoms, target AD hallmarks, and target moieties to diagnose AD. We also highlight NP-based immunotherapy, which has recently gained special attention as a potential treatment option to disrupt AD progression. Overall, this review focuses on recently investigated NP systems that represent innovative strategies to understand AD pathogenesis and suggests treatment and diagnostic modalities to cure AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics14040835

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic representation of potential pathways of NP-based drug delivery systems that penetrate the BBB for the treatment of AD.
Figure 1 Schematic representation of potential pathways of NP-based drug delivery systems that penetrate the BBB for the treatment of AD.CC BY · PubMed Central
Figure 2 Illustration of the action mechanism of NPs in neurons associated with AD after overcoming the BBB. (A) Liposome with loaded AchE inhibitors targeting cholinergic system impairment, (B) 1. SLNP-loaded anti-tau drug with functionalized phosphatidylserine targeting hyper-phosphorylated tau proteins, (B) 2. PLGA-PEG with anti-Aβ antibody is involved in targeting, solubilizing, and clearing Aβ fibrils, (C) Modified AuNP with capture antibody targeting Aβ and tau proteins, making a sandwich with secondary antibody for diagnosing hallmarks associated with AD. AchE, acetylcholinesterase; NMDA, N-methyl D-aspartate antagonist; Aβ, amyloid beta fragment, PEG, polyethylene glycol; SLNP, solid lipid nanoparticle, NP, nanoparticle; PLGA, poly D,L-lactic-co-glycolic acid; AuNP, gold nanoparticle.
Figure 2 Illustration of the action mechanism of NPs in neurons associated with AD after overcoming the BBB. (A) Liposome with loaded AchE inhibitors targeting cholinergic system impairment, (B) 1. SLNP-loaded anti-tau drug with functionalized phosphatidylserine targeting hyper-phosphorylated tau proteins, (B) 2. PLGA-PEG with anti-Aβ antibody is involved in targeting, solubilizing, and clearing Aβ fibrils, (C) Modified AuNP with capture antibody targeting Aβ and tau proteins, making a sandwich with secondary antibody for diagnosing hallmarks associated with AD. AchE, acetylcholinesterase; NMDA, N-methyl D-aspartate antagonist; Aβ, amyloid beta fragment, PEG, polyethylene glycol; SLNP, solid lipid nanoparticle, NP, nanoparticle; PLGA, poly D,L-lactic-co-glycolic acid; AuNP, gold nanoparticle.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 194 references

Research works printed but not linked: 1

  1. Chung, E.J., Leon, L., and Rinaldi, C. (2020). Chapter 21—Nanoemulsions. Nanoparticles for Biomedical Applications, Elsevier.

Cited by

See all 141

Metadata

Authors
Poudel, P., & Park, S.
Affiliations
Keimyung University (KR)
Corresponding author
Park, Soyeun
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2022-04-11
Volume
14
Issue
4
Pages
835
ISSN
1999-4923 (ISSN-L)
OpenAlex
W4223478480
Cited by
124
References
195
Citations by year
2026: 28 · 2025: 37 · 2024: 33 · 2023: 17 · 2022: 9
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Pharmaceutics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Keimyung University (2019)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
Keywords
Alzheimer's disease, nanoparticle drug delivery, blood-brain barrier, liposomes, micelles, polymeric nanoparticles, solid lipid nanoparticles, inorganic nanoparticles, Alzheimer's disease therapeutics, Alzheimer's disease diagnosis, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. https://app.cochat.ai/papers/10.3390/pharmaceutics14040835
The paper
Poudel, P., & Park, S. (2022). Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics. https://doi.org/10.3390/pharmaceutics14040835

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.